Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Ekaterine Arkania
Observed names:
Arkania, Ekaterine,
E. Arkania,
ekaterine arkania
ORCID:
0009-0001-5682-9753
Observed ORCID:
0009-0001-5682-9753
OpenAlex ID:
A5019928825
Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial
2022
·
Ying Cheng
, Liang Han
, et al.
·
JAMA
·
562
Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial
2024
·
Mafalda Oliveira
, Denys Pominchuk
, et al.
·
The Lancet Oncology
·
157
A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004)
2024
·
Caicun Zhou
, Yanping Hu
, et al.
·
Cancer Cell
·
88
Abstract GS3-02: GS3-02 Camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose Phase 2 SERENA-2 trial
2023
·
Mafalda Oliveira
, Denys Pominchuck
, et al.
·
Cancer Research
·
80
Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy
2019
·
Lee Schwartzberg
, Rudolph Navari
, et al.
·
The Oncologist
·
35
PDF
First‐line serplulimab plus chemotherapy in extensive‐stage small‐cell lung cancer: Updated results and biomarker analysis from the ASTRUM‐005 randomized clinical trial
2025
·
Ying Cheng
, Shuang Zhang
, et al.
·
癌症:英文版
·
32
PDF
Clinical activity of camizestrant, a next-generation SERD, versus fulvestrant in patients with a detectable ESR1 mutation: Exploratory analysis of the SERENA-2 phase 2 trial.
2023
·
Mafalda Oliveira
, Denys Pominchuk
, et al.
·
Journal of Clinical Oncology
·
21
Abstract RF01-01: SERENA-3: A randomized pre-surgical window of opportunity study assessing dose and duration of camizestrant treatment in post-menopausal women with ER-positive, HER2-negative primary breast cancer
2024
·
John Robertson
, Teimuraz Gogitidze
, et al.
·
Cancer Research
·
8
154TiP TACTIVE-N: Open-label, randomized, noncomparative neoadjuvant phase 2 study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, or anastrozole in postmenopausal women with ER+/human epidermal growth factor receptor 2 (HER2)- localized breast cancer
2023
·
P.A. Fasching
, K. Clifton
, et al.
·
ESMO Open
·
7
PDF
First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer: Secondary Analysis of the ASTRUM-005 Phase 3 Randomized Clinical Trial
2026
·
Jingjing Liu
, Liang Han
, et al.
·
JAMA Oncology
·
5
2MO Dynamics of ESR1 mutation (ESR1m) circulating tumour DNA (ctDNA) in patients (pts) with estrogen receptor (ER)+ HER2- metastatic breast cancer (mBC) receiving camizestrant or fulvestrant: Exploratory analyses from the SERENA-2 trial
2024
·
M. Oliveira
, E.P. Hamilton
, et al.
·
ESMO Open
·
5
PDF
Pharmacodynamics of Camizestrant Treatment in Postmenopausal Women With Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Primary Breast Cancer: Results From the Randomized, Presurgical SERENA-3 Study
2026
·
John F.R. Robertson
, Teimuraz Gogitidze
, et al.
·
Journal of Clinical Oncology
·
4
293MO TACTIVE-N: Phase 2 study of neoadjuvant vepdegestrant, a PROteolysis TArgeting chimera (PROTAC) estrogen receptor (ER) degrader, or anastrozole in postmenopausal ER+/human epidermal growth factor receptor 2 (HER2)- localized breast cancer (BC)
2025
·
P.A. Fasching
, B. Bermejo
, et al.
·
Annals of Oncology
·
3
Abstract PS2-05: PRESERVE 2: A randomized, phase 3, double-blind trial of trilaciclib or placebo in patients (pts) receiving first-line gemcitabine/carboplatin (GCb) for locally advanced or metastatic triple-negative breast cancer (mTNBC)
2025
·
Shom Goel
, Joyce O’Shaughnessy
, et al.
·
Clinical Cancer Research
·
2
OA09.05 A Phase 3 Study of Serplulimab Plus Chemotherapy as First-Line Treatment for Squamous Non-small-Cell Lung Cancer (ASTRUM-004)
2023
·
C. Zhou
, Y. Hu
, et al.
·
Journal of Thoracic Oncology
·
1
PDF
2753eP Health-related quality of life in the phase 3 trial ASTRUM-004 of first-line serplulimab plus chemotherapy for locally advanced or metastatic squamous non-small cell lung cancer
2026
·
A. Xiong
, Y. Hu
, et al.
·
Annals of Oncology
Papillary thyroid carcinoma association with high risk of developing luminal a- and b molecular type breast cancer : retrospective study based on 1500 cases
2026
·
Lali Tigishvili
, Abo Gachechiadze
, et al.
·
Endocrine Abstracts
Phase 2 peri-operative study of fianlimab + cemiplimab + chemotherapy versus cemiplimab + chemotherapy in resectable early-stage non-small cell lung cancer (NSCLC).
2025
·
Ekaterine Arkania
, Tamta Makharadze
, et al.
·
Journal of Clinical Oncology
P4.11D.09 Fianlimab-Based Combination Therapies in Patients with Advanced Non-Small Cell Lung Cancer: Trials in Progress Updates
2024
·
T. Melkadze
, M. Gogishvili
, et al.
·
Journal of Thoracic Oncology
PDF
152P Exploratory biomarker analysis of phase III ASTRUM-004 study: Serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer
2024
·
C. Zhou
, Y. Hu
, et al.
·
Annals of Oncology
PDF
274P A multiomic approach for camizestrant-induced estrogen receptor (ER) degradation, antagonism and anti-proliferation: Exploratory analysis from SERENA-3
2024
·
G. Dzagnidze
, C. Morrow
, et al.
·
Annals of Oncology
PDF
Relapse and Metastatic Spread Patterns in Patients with HER2/neu Positive Breast Cancer who Underwent Targeted Therapy
2017
·
Ekaterine Arkania
, Nino Chichua
·
The Breast
Show more works
View as search
Works count:
23
Citation count:
1,022
H-index:
8
I10-index:
8
Year
Topic
Type